Tempol (MBM-02)

· Adamis Pharmaceuticals Corporation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tempol (MBM-02), covering 2022-12-06 to 2022-12-06. Get the full timeline:

Most recent: Clinical Trial Update: Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients. [Phase 2, Phase 3]